RT Book, Section
A1 Attar, Eyal C.
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127647715
T1 Myelodysplastic Syndromes
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127647715
RD 2024/10/06
AB Myelodysplastic  syndromes  (MDS)  represent  premalignant  entities  that  share  many  characteristics  with  acute  myeloid  leukemia  (AML).  These  clonal  hematopoietic  stem  cell  (HSC)  disorders  are  characterized  by  pancytopenia  resulting  from  failure  of  normal  hematopoiesis.  The  bone  marrow  shows  hypercellularity,  arrested  maturation  in  one  or  more  cellular  lineages,  and  an  increase  in  bone  marrow  myeloid  precursors.  Clinical  symptoms  result  from  cytopenias.  Approximately  one-third  of  patients  ultimately  progress  to  AML.  Treatment  involves  supportive  care  and  the  use  of  agents  capable  of  ameliorating  cytopenias  and  delaying  development  of  AML.  However,  hematopoietic  stem  cell  transplantation  (HCT)  represents  the  only  potentially  curative  treatment  for  MDS.